TITLE

Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres

AUTHOR(S)
Edgar Tissot; Albert Faradji; Karine Demesmay; Marie Bertrand; Jean-Louis Lorenzini; Marie-Elisabeth Briquel; Patricia Pouzol
PUB. DATE
June 2008
SOURCE
Pharmacy World & Science;Jun2008, Vol. 30 Issue 3, p287
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Abstract   Objective The aim of this study was to assess the consumption of anti-haemophilic drugs by adults and children with severe haemophilia A or B (residual activity of FVIII or FIX ≤2%) and to quantify the average direct medical costs. Method A retrospective multicentre cost-of-illness study from the perspective of French national health insurance system. The costs include only the use of clotting factors. Main outcome measure Consumption was expressed in UI/kg/year and costs in euros/kg/year. Results From January 1, 2001 to December 31, 2002, data from 81 adults and 30 children with severe haemophilia A (n = 92) or B (n = 19) and included in the “SNH” were collected and analysed. A coagulation factor inhibitor was present in 10 patients (9%). Four of them were high responders. Mean age and body weight were respectively 28 ± 17 years and 58 ± 24 kg. Except for one adult patient, all (99%) had outpatient treatment, 44 patients (40%) were hospitalized and treated by recombinant or/and plasma-derived FVIII or FIX or/and rFVIIa. Overall median annual consumption of anti-haemophilic drugs per patient was estimated at 1,333 UI/kg, with a median cost-of-illness of 1,156 euros/kg. Patients with severe haemophilia B consumed more than patients with severe haemophilia A, though not significantly (P = 0.096), with a median of 2,167 vs. 1,100 UI/kg/year and a median cost of 1,760 vs. 917 euros/kg/year (P = 0.13). Children consumed respectively more than adults (P = 0.008), with a median of 3,204 vs. 1,106 UI/kg/year and a median cost of 2,614 vs. 913 euros/kg/year (P = 0.012). The median cost for patients with an inhibitor was 3,291 euros/kg/year, approximately threefold higher than that of patients without an inhibitor (926 euros/kg/year) (P = 0.022). Conclusion It suggests a higher consumption and cost of anti-haemophilic drugs among children when compared to adults. Haemophilia B patients did not consume significantly more than haemophilia A patients, whereas the consumption and cost for patients with or without inhibitors differed significantly.
ACCESSION #
32804997

 

Related Articles

  • Rotation Thromboelastography for Assessment of Hypercoagulation and Thrombosis in Patients with Cardiovascular Diseases. Dimitrova-Karamfilova, Antoaneta; Patokova, Yuliana; Solarova, Tania; Petrova, Irina; Natchev, Gencho // Journal of Life Sciences;Jan2012, Vol. 6 Issue 1, p28 

    Hypercoagulation is not detected in clinical practice with routinely performed blood coagulation tests. More advanced laboratory analyses to detect or monitor hypercoagulation have not yet been introduced into routine clinical management. Thromboelastography assesses the influence of plasma...

  • Survival Analysis of Hemophilia-Associated AIDS Cases in the US. Stehr-Green, Jeanette K.; Holman, Robert C.; Mahoney, Maureen A. // American Journal of Public Health;Jul1989, Vol. 79 Issue 7, p832 

    Abstract: Using national hemophilia-associated AIDS (acquired immunodeficiency syndrome) surveillance data and the life table method of survival analysis, the median length of survival of hemophilic patients in the United States after the diagnosis of AIDS was 11.7 months; the cumulative...

  • Blood component therapy guided by celite-activated thromboelastography for perioperative coagulopathy. Kawasaki, Jun; Tanaka, Kenichi A.; Sato, Nobukazu; Saitoh, Toshie; Shimizu, Masahiro; Kawazoe, Taro // Journal of Anesthesia;2002, Vol. 16 Issue 1, p79 

    Presents the case of patients in whom on-site thromboelastography was used to monitor blood coagulation status for perioperative coagulopathy. Medical histories of the patients; Results of laboratory examinations; Outcome of treatments.

  • Surgical implications of hypercoagulable syndromes. Gable, Dennis R.; Bergamini, Thomas M. // American Surgeon;Feb1997, Vol. 63 Issue 2, p163 

    Reports that hypercoagulable states are being recognized as a cause of both venous and arterial thrombosis. Relation between morbidity and mortality, and the care of surgical patients with venous and arterial thrombosis secondary to a primary hypercoagulable; Reviews of the records of all...

  • Severe Coagulopathy as a Consequence of Smoking Crack Cocaine Laced with Rodenticide.  // New England Journal of Medicine;12/20/2001, Vol. 345 Issue 25, p1860 

    A correction to the article "Severe Coagulopathy as a Consequence of Smoking Crack Cocaine Laced With Rodenticide" that was published in the August 30, 2001 issue is presented.

  • Prothrombotic Coagulation Abnormalities Preceding the Hemolytic—Uremic Syndrome.  // New England Journal of Medicine;2/28/2002, Vol. 346 Issue 9, p715 

    A correction to the article "Prothrombotic Coagulation Abnormalities Preceding the Hemolytic– Uremic Syndrome," that was published in the January 3, 2002 issue is presented.

  • A chamber of hope for hemophilia. Pipe, Steven W.; Kaufman, Randal J. // Nature Biotechnology;Mar2000, Vol. 18 Issue 3, p264 

    Focuses on the blood coagulation disorder hemophilia. Cause of the disease; Role of genetic engineering in treating hemophiliacs; Side effects of the treatment; Method devised by Ton-That and coworkers to overcome the obstacles.

  • Hemophilia bypassed. DeWitt, Natalie // Nature Biotechnology;Mar2000, Vol. 18 Issue 3, p251 

    Focuses on the blood coagulation disorder hemophilia, caused by deficiencies or defects of blood coagulation factors. Side effects of therapies based on replacement of defective plasma proteins; Limitations of using recombinant Factor VIIa in the treatment of the disease; Development of an...

  • A Guide to Disorders of Hemostasis. Goulian, Mehran // Annals of Internal Medicine;Oct66, Vol. 65 Issue 4, p782 

    Presents a guide for the diagnosis and treatment of hemostasis disorders. Areas of hemostatic mechanisms; Hypothetical scheme for mechanism of blood coagulation; Classification of hemostasis disorders.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics